initially demonstrated in the mid-1980s, 3 or an aromatase inhibitor (AI). Beginning in 2005, recommendations from ASCO suggested that adjuvant therapy for postmenopausal women with HR+ breast cancer include an AI, either alone or in sequence after
Search Results
John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin
Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta
intuitively would delay the initiation of adjuvant therapy. Patients with underweight BMI may be sarcopenic, which leads to increased postoperative complications. 26 Being underweight at diagnosis has been shown as an independent, adverse prognostic factor in
Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin
therapy referred to starting chemotherapy and RT within 14 days of each other, with the remainder designated as sequential. 25 , 26 Patients with an interval of >6 months from surgery to adjuvant therapy, or between adjuvant RT and chemotherapy, were
Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta
intuitively would delay the initiation of adjuvant therapy. Patients with underweight BMI may be sarcopenic, which leads to increased postoperative complications. 26 Being underweight at diagnosis has been shown as an independent, adverse prognostic factor in
Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns
pCR, and the demonstrated toxicity in the adjuvant phase of treatment, clinicians may discuss potential benefits versus toxicity with individuals to determine whether to continue adjuvant pembrolizumab. What Adjuvant Therapies Should Be Given to
Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults
involvement (69%), and without perineural invasion (96%) or lymphovascular invasion (94%). Most tumors were primarily resected (81%), and most adjuvant therapy was used in higher T-class cases (see supplemental eTable 2) . Of patients undergoing excision, 15
Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng
adjuvant therapy has been shown to negatively impact outcomes in stage III colon cancer 5 and stage I–III breast cancer. 6 Although a few studies have found a paradoxical relationship of shorter treatment initiation intervals correlating with
Amanda N. Fader
extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i
Eric Jonasch
is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies
